Document is current
Any future updates will be listed below
-
Authors
Khani, Mohammadreza
Burla, Goutham Kumar Reddy
Sass, Lucas R.
Arters, Ostin N.
Xing, Tao
Wu, Haiming
Martin, Bryn A. https://orcid.org/0000-0003-1234-7880
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (P20GM1033408, 4U54GM104944)
Biogen
- License Information
-
More Information
Article History
Received: 5 November 2021
Accepted: 3 January 2022
First Online: 28 January 2022
Declarations
:
: Not applicable.
: All authors have approved the manuscript submission. The content of this manuscript has not been published or submitted for publication elsewhere.
: BAM is an employee at Alcyone Therapeutics. BAM has received research funding from Biogen Inc., Genentech Inc., Voyager Therapeutics, KBR Wyle, Alcyone Lifesciences Inc., Minnetronix Inc. and Voyager Therapeutics. BAM has served as a consultant to Flux Neuroscience, Genentech, Roche, Minnetronix, SwanBio Therapeutics, Praxis Medicines, Cerebral Therapeutics, CereVasc, InviCRO, Neurosyntec, Behavior Imaging, and Voyager Therapeutics. BAM has served as a scientific advisory board member to Alcyone Lifesciences, Anuncia Medical, Chiari and Syringomyelia Foundation, The International Society for Hydrocephalus and CSF Disorders, and The International CSF Dynamics Society.
